Rachel Schlichting
Family · Waterloo, IANPI 1598179756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. E.r. Squibb & Sons, L.L.C. accounts for 79.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $730 and has fallen 64.0% since, to $263 in 2025.
Across 79 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Sanofi$54
- Regeneron Healthcare Solutions, Inc.$42
- Stryker$28
- Radius Health, Inc.$27
- SPR Therapeutics, Inc$26
- plus $114 from 8 others
What the payments were for
- Food & beverage$1,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 63 | $1,113 |
| Sanofi | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Stryker | 1 | $28 |
| Radius Health, Inc. | 1 | $27 |
| SPR Therapeutics, Inc | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Vertex | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Solventum Corporation | 1 | $14 |
| GSK | 1 | $13 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Orthofix Medical, Inc. | 1 | $4 |
How this compares
$1,403 in reported general payments places this provider in the 85th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 20 | $214 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $145 |
| Meloxicam | 53 | $130 |
| Ropinirole Hcl | 12 | $109 |
| Tramadol Hcl | 29 | $79 |
| Oxycodone Hcl | 22 | $77 |
| Amoxicillin | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other family in Waterloo
- Chi-Ying SageWaterloo$14K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.